According to media reports,

Chen Wei's team's progress in restructuring the new crown vaccine is typical

The phase I clinical trial was launched on March 16, which is the first new coronal vaccine to enter the clinical research stage in the world.

A phase II clinical trial was initiated on 12 April.

On August 11, it was granted the national patent, and it was the first new crown vaccine to enter clinical practice and obtain the patent right.

According to who data,More than 30 kinds of new coronal vaccines have entered the clinical trial stage in the world, of which 9 are in the phase III clinical trial stage, and the pit and fissure account for more than half.

Chen Wei previously said that large-scale production of the recombinant new crown vaccine has been carried out since the phase I clinical trial, and the annual production target of 300 million yuan can be achieved. Meanwhile, the recombinant new crown vaccine can completely cover the mutated new coronavirus.

Besides,The two new crown inactivated vaccines of sinopharma Group China biology have also entered the phase III clinical trial stageIn the United Arab Emirates, Bahrain, Peru, Morocco, Argentina and other countries and regions.

According to the current data, the inactivated vaccine can cover the virus strains in Xinfa District of Beijing, Xinjiang, or Europe, with good effectiveness.